BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™ is pleased to announce that as of August 15, 2018, the Arizona Heart Rhythm Center will be the first organization in the state of Arizona to offer automated remote monitoring of cardiac implantable electronic devices (CIEDs) such as pacemakers, defibrillators, and loop recorders via the PaceMate™ software […]
Rhythm
BioSig Technologies Announces FDA 510(k) Clearance for PURE EP System
Santa Monica, CA, Aug. 14, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), announced that the Company has received 510(k) clearance for its first product, PURE EP System, from the U.S. Food and Drug Administration (FDA). The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring […]
Garmin® Health and Cardiogram announce integration of Cardiogram Heart Health app and Garmin wearables
OLATHE, Kan.–(BUSINESS WIRE)–Garmin International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), today announced that the Cardiogram heart health app is now compatible with all Garmin wearables featuring optical heart rate, including many of the latest fēnix®, Forerunner®, and vívo series devices. The Cardiogram app provides advanced insights based on […]
Medtronic Begins Pilot Study of Investigational Extravascular ICD System
DUBLIN – August 9, 2018 – Medtronic plc (NYSE:MDT) today announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver lifesaving defibrillation and antitachycardia pacing therapy all in one system, […]
N8 Medical Announces NHLBI Grant to Develop Antimicrobial Pacemaker Envelope
DUBLIN, Ohio, Aug. 7, 2018 /PRNewswire/ — N8 Medical, LLC (N8 Medical) today announced that the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) indicated its intent to fund N8 Medical’s STTR Phase I grant application for the development of a resorbable envelope to prevent surgical site […]
Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
MONTREAL, Aug. 8, 2018 /PRNewswire/ — Milestone Pharmaceuticals, a clinical-stage cardiovascular company, today announced that the first patient has been randomized in its Phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel blocker administered intranasally by the patient designed to terminate paroxysmal supraventricular tachycardia (PSVT) episodes wherever […]
PaceMate™ Partners with SeaMercy on Pacific Islands Healthcare Mission
BRADENTON, Fla.–(BUSINESS WIRE)–PaceMateTM announces today the volunteer partnership between CEO Kevin R. Campbell, MD, FACC, and SeaMercy, an Oregon-based charity committed to providing medical relief to underprivileged natives in the South Pacific. PaceMateTM is a compassion-driven digital healthcare company committed to providing fully integrated remote monitoring services for cardiac implantable electronic devices […]
VisCardia Announces First Implant of the VisONE® System for Treating Heart Failure
PORTLAND, Ore.–(BUSINESS WIRE)–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and the commencement of its VisONE Heart Failure pilot study in Ukraine. The VisONE implantable system delivers VisCardia’s proprietary Asymptomatic Diaphragmatic Stimulation (ADS) therapy to improve cardiac […]
Medtronic Receives FDA Approval for Implantable System for Remodulin® to Treat Patients with Pulmonary Arterial Hypertension
DUBLIN – July 31, 2018 – Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary arterial hypertension (PAH). Through a first-of-its-kind collaboration, the Medtronic SynchroMed(TM) II drug delivery system and cardiac catheter technologies were leveraged to […]
Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treated
DANVERS, Mass., July 26, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, announced the Impella 2.5®, Impella CP® and Impella 5.0® heart pumps received Central Drugs Standard Control Organization (CDSCO) approval in India for use during high-risk percutaneous coronary intervention (PCI), cardiogenic shock, and […]



